Flupirtine Analogue Synthesis and Screening for the Treatment of Chemotherapy-Induced Neuropathic Pain
- Institution
- University of Nebraska Medical Center, NE
- Principal investigator
- Bin Duan
- Funding
- $179K
- Duration
- 2025–2027
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Chemotherapy-induced neuropathic pain (CINP) is a common side effect for cancer patients and can greatly reduce patients’ quality of life. Although a wide range of pharmacological agents have been investigated in clinical trials as potential CINP therapies, currently approved analgesics for neuropathic pain are inadequate and offer limited beneficial effects in ameliorating CINP. Flupirtine, a non-opioid and non-steroidal anti- inflammatory drug analgesic, can effectively relieve various pain conditions in clinical studies. However, safety concerns, particularly rare but severe liver toxicity, led to restrictions on its use and eventual withdrawal from the market in the U.S. The adverse side effects of flupirtine that induce hepatotoxicity have been shown to not be linked with the primary antinociceptive mechanism of action. We have developed a flupirtine analogue library and demonstrated that one of the compounds (compound 5) had a much faster metabolism rate than the flupirtine parent and did not induce hepatotoxicity after intraperitoneal injection. We have also successfully developed both short-term and long-term mouse CINP models. Our results showed that compound 5 effectively ameliorated short-term CINP, as evidenced by various pain behavior tests. In this proposal, we will further synthesize and screen flupirtine analogues through structural modification to enhance their liver safety profile while maintaining or even improving therapeutic efficacy to effectively relieve CIPN. The specific aims of the studies are (1) to strategically develop potent Kv7.2/7.3 activators unable to form hepatotoxic metabolites, (2) to determine the analgesic efficacies of flupirtine analogues in the CINP mouse models. This proposal will develop a series of novel flupirtine analogues with reduced or eliminated hepatotoxicity as non-opioid analgesics to relieve CINP and treat various other pain conditions and non-pain-related diseases.
Research team
- Bin DuanPI
- Paul TrippierPI
LOADING MOONBASE SCORE
Questions for University of Nebraska Medical Center
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Oakland University73
Development and Characterization of Small Molecule Activators of Peptidase Neurolysin for Stroke Therapy
Thomas J Abbruscato · $646K · 2018–2030
- NIH · University of Nebraska Medical Center65
Discovery and characterization of selective GIRK1/2 activators and their evaluation in preclinical models of pain
Jerod S. Denton · $546K · 2022–2028
- NIH · University of Nebraska Medical Center48
DNA ligase activities during base excision repair coordination
Melike Caglayan · $153K · 2022–2027